Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

Old_Man_59 Jul. 25 at 8:14 PM

$IMUX

1 · Reply

AitorMenta Jul. 25 at 8:11 PM

$IMUX day 2

0 · Reply

cbowers8171 Jul. 25 at 7:56 PM

$IMUX really nice week 🔥

0 · Reply

Cattitude Jul. 25 at 6:43 PM

$IMUX

0 · Reply

Bulltrader988 Jul. 25 at 6:40 PM

$IMUX ...👃👀

0 · Reply

Pipelinepivots Jul. 25 at 5:42 PM

TGL The best setups don’t shout they whisper. And this one’s whispering: “AI. Blockchain. Users. Q3 Launch. Under $2.” You either listen early, or chase late. I’ve already moved. $REVB $QH $IMUX $MN

0 · Reply

CaptDragon_Redneck Jul. 25 at 5:40 PM

$IMUX and $GOSS the best bios right imo.

0 · Reply

Starflash Jul. 25 at 4:29 PM

$IMUX Being with IMUX for several years it feels like Groundhog Day. I don’t know how many times we already passed this mark, hoping that THIS time we will never see it again…

3 · Reply

Stock_AHA Jul. 25 at 3:48 PM

$IMUX one step at a time Baby steps but slowly, but surely

0 · Reply

Invest2live Jul. 25 at 2:22 PM

$HCTI 1207% already; congrats 🎊🎈🎉 🌿 Checkout $LCTX and $IMUX and $BITF

0 · Reply

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 6 weeks ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 7 weeks ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 7 weeks ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 7 weeks ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 2 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 2 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 3 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 3 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 3 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 4 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 5 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 5 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 5 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 6 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 7 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 8 months ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 9 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 9 months ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 9 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 9 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 9 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 9 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 11 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 11 months ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 11 months ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Feb 22, 2024, 3:38 PM EST - 1 year ago

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Jan 5, 2024, 6:35 AM EST - 1 year ago

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Jan 5, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Nov 21, 2023, 6:30 AM EST - 1 year ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

Nov 14, 2023, 10:53 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript

Old_Man_59 Jul. 25 at 8:14 PM

$IMUX

1 · Reply

AitorMenta Jul. 25 at 8:11 PM

$IMUX day 2

0 · Reply

cbowers8171 Jul. 25 at 7:56 PM

$IMUX really nice week 🔥

0 · Reply

Cattitude Jul. 25 at 6:43 PM

$IMUX

0 · Reply

Bulltrader988 Jul. 25 at 6:40 PM

$IMUX ...👃👀

0 · Reply

Pipelinepivots Jul. 25 at 5:42 PM

0 · Reply

CaptDragon_Redneck Jul. 25 at 5:40 PM

$IMUX and $GOSS the best bios right imo.

0 · Reply

Starflash Jul. 25 at 4:29 PM

$IMUX Being with IMUX for several years it feels like Groundhog Day. I don’t know how many times we already passed this mark, hoping that THIS time we will never see it again…

3 · Reply

Stock_AHA Jul. 25 at 3:48 PM

$IMUX one step at a time Baby steps but slowly, but surely

0 · Reply

Invest2live Jul. 25 at 2:22 PM

$HCTI 1207% already; congrats 🎊🎈🎉 🌿 Checkout $LCTX and $IMUX and $BITF

0 · Reply

Invest2live Jul. 25 at 2:11 PM

$HCTI 1262% already; congrats 🎈🎊🎉🌿 Checkout $IMUX and $LCTX as well as $MU and $TTD

1 · Reply

Whyasking Jul. 25 at 1:57 PM

$IMUX

0 · Reply

NVDAMillionaire Jul. 25 at 12:17 AM

$IMUX Really good write-up that perfectly summarizes IMUX's present situation. So if you want to bring your IMUX knowledge up to date or just discover IMUX, this is required reading. https://beyondspx.com/article/immunic-s-dual-action-pipeline-poised-for-transformation-after-key-data-readouts-nasdaq-imux

1 · Reply

Tradergrows Jul. 24 at 11:41 PM

$IMUX 6/24 I said we’d be back over $1.00. 7/24 here we are. Weird eh? Perhaps the next test will be how long we can hold. Let's see.

0 · Reply

Old_Man_59 Jul. 24 at 8:08 PM

$IMUX 1 down 9 to go!!

0 · Reply

Krag2020 Jul. 24 at 6:12 PM

$IMUX alright! Go go go

0 · Reply

TungstenHands Jul. 24 at 6:05 PM

$IMUX Send it!

0 · Reply

radonco Jul. 24 at 6:02 PM

$IMUX ENSURE phase 3 studies fully enrolled with over 2200 RMS patients worldwide…data later in 2026…I ensure it will be positive! MC should be $1B which is at least $10.

1 · Reply

biogenetic Jul. 24 at 5:59 PM

$IMUX 🤔

0 · Reply

Jw242 Jul. 24 at 5:55 PM

$IMUX volume candelabra

0 · Reply

Bulltrader988 Jul. 24 at 5:48 PM

$IMUX ... and now Im sniffing $1.80 👃👀

0 · Reply

Easteregg01 Jul. 24 at 5:37 PM

$IMUX today could be the 1st one above 1$

0 · Reply

Market Cap	95.53M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	971,400
Avg Vol	1,812,854
Day's Range	N/A - N/A
Shares Out	95.82M
Stochastic %K	90%
Beta	1.49
Analysts	Strong Sell
Price Target	$7.63